{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T16:28:35Z","timestamp":1794068915842,"version":"4.8.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","award":["FP17016"],"award-info":[{"award-number":["FP17016"]}],"id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA221703-05"],"award-info":[{"award-number":["P50CA221703-05"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["134148-MRAT-19-168-01"],"award-info":[{"award-number":["134148-MRAT-19-168-01"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["687055"],"award-info":[{"award-number":["687055"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"DOI":"10.1186\/s40478-025-01978-1","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T22:40:06Z","timestamp":1744670406000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrated analysis of molecular and clinical features associated with overall survival in melanoma patients with brain metastasis"],"prefix":"10.1186","volume":"13","author":[{"given":"Swaminathan","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith S.","family":"Pelster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Hasanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato A.","family":"Guerrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney W.","family":"Hudgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora A.","family":"Ledesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuchenchu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant M.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Haydu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalman V.","family":"Katlowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. N. Vashisht","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"McQuade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence N.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason T.","family":"Huse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Lazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Tetzlaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Gershenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aron Y.","family":"Joon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prahlad T.","family":"Ram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherise D.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"issue":"6","key":"1978_CR1","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3322\/caac.21352","volume":"66","author":"MK Tripp","year":"2016","unstructured":"Tripp MK, Watson M, Balk SJ, Swetter SM, Gershenwald JE (2016) State of the science on prevention and screening to reduce melanoma incidence and mortality: the time is now. CA Cancer J Clin 66(6):460\u2013480","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"1978_CR2","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1158\/2159-8290.CD-18-1489","volume":"9","author":"GM Fischer","year":"2019","unstructured":"Fischer GM, Jalali A, Kircher DA et al (2019) Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases. Cancer Discov 9(5):628\u2013645","journal-title":"Cancer Discov"},{"issue":"6","key":"1978_CR3","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/pcmr.13059","volume":"35","author":"A Karz","year":"2022","unstructured":"Karz A, Dimitrova M, Kleffman K et al (2022) Melanoma central nervous system metastases: an update to approaches, challenges, and opportunities. Pigment Cell Melanoma Res 35(6):554\u2013572","journal-title":"Pigment Cell Melanoma Res"},{"issue":"8","key":"1978_CR4","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/cncr.25634","volume":"117","author":"MA Davies","year":"2011","unstructured":"Davies MA, Liu P, McIntyre S et al (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117(8):1687\u20131696","journal-title":"Cancer"},{"issue":"2","key":"1978_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1215\/15228517-2007-058","volume":"10","author":"JJ Raizer","year":"2008","unstructured":"Raizer JJ, Hwu WJ, Panageas KS et al (2008) Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 10(2):199\u2013207","journal-title":"Neuro Oncol"},{"issue":"7","key":"1978_CR6","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/neuonc\/noac251","volume":"25","author":"M Hasanov","year":"2023","unstructured":"Hasanov M, Milton DR, Davies AB et al (2023) Changes in outcomes and factors associated with survival in melanoma patients with brain metastases. Neuro Oncol 25(7):1310\u20131320","journal-title":"Neuro Oncol"},{"issue":"21","key":"1978_CR7","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.1158\/1078-0432.CCR-13-3003","volume":"20","author":"G Chen","year":"2014","unstructured":"Chen G, Chakravarti N, Aardalen K et al (2014) Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res 20(21):5537\u20135546","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1978_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cam4.50","volume":"2","author":"H Niessner","year":"2013","unstructured":"Niessner H, Forschner A, Klumpp B et al (2013) Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med 2(1):76\u201385","journal-title":"Cancer Med"},{"issue":"1","key":"1978_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/pcmr.12424","volume":"29","author":"H Seifert","year":"2016","unstructured":"Seifert H, Hirata E, Gore M et al (2016) Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases. Pigment Cell Melanoma Res 29(1):92\u2013100","journal-title":"Pigment Cell Melanoma Res"},{"issue":"5","key":"1978_CR10","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1158\/2159-8290.CD-21-1006","volume":"12","author":"K Kleffman","year":"2022","unstructured":"Kleffman K, Levinson G, Rose IVL et al (2022) Melanoma-secreted amyloid beta suppresses neuroinflammation and promotes brain metastasis. Cancer Discov 12(5):1314\u20131335","journal-title":"Cancer Discov"},{"issue":"14","key":"1978_CR11","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1016\/j.cell.2022.06.007","volume":"185","author":"J Biermann","year":"2022","unstructured":"Biermann J, Melms JC, Amin AD et al (2022) Dissecting the treatment-naive ecosystem of human melanoma brain metastasis. Cell 185(14):2591\u20132608","journal-title":"Cell"},{"issue":"9","key":"1978_CR12","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1158\/2159-8290.CD-19-1228","volume":"10","author":"B Ngo","year":"2020","unstructured":"Ngo B, Kim E, Osorio-Vasquez V et al (2020) Limited environmental serine and glycine confer brain metastasis sensitivity to PHGDH inhibition. Cancer Discov 10(9):1352\u20131373","journal-title":"Cancer Discov"},{"issue":"12","key":"1978_CR13","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1158\/2159-8290.CD-19-0270","volume":"9","author":"Y Zou","year":"2019","unstructured":"Zou Y, Watters A, Cheng N et al (2019) Polyunsaturated fatty acids from astrocytes activate PPARgamma Signaling in cancer cells to promote brain metastasis. Cancer Discov 9(12):1720\u20131735","journal-title":"Cancer Discov"},{"issue":"4","key":"1978_CR14","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s43018-021-00183-y","volume":"2","author":"GB Ferraro","year":"2021","unstructured":"Ferraro GB, Ali A, Luengo A et al (2021) Fatty acid synthesis is required for breast cancer brain metastasis. Nat Cancer 2(4):414\u2013428","journal-title":"Nat Cancer"},{"key":"1978_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaa177","author":"GM Fischer","year":"2021","unstructured":"Fischer GM, Guerrieri RA, Hu Q et al (2021) Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases. Neurooncol Adv. https:\/\/doi.org\/10.1093\/noajnl\/vdaa177","journal-title":"Neurooncol Adv"},{"issue":"8","key":"1978_CR16","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJM199002223220802","volume":"322","author":"RA Patchell","year":"1990","unstructured":"Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322(8):494\u2013500","journal-title":"N Engl J Med"},{"issue":"3","key":"1978_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00701-013-1619-y","volume":"155","author":"CH Lee","year":"2013","unstructured":"Lee CH, Kim DG, Kim JW et al (2013) The role of surgical resection in the management of brain metastasis: a 17\u00a0year longitudinal study. Acta Neurochir (Wien) 155(3):389\u2013397","journal-title":"Acta Neurochir (Wien)"},{"issue":"8","key":"1978_CR18","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/S1470-2045(17)30414-X","volume":"18","author":"A Mahajan","year":"2017","unstructured":"Mahajan A, Ahmed S, McAleer MF et al (2017) Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1040\u20131048","journal-title":"Lancet Oncol"},{"issue":"6","key":"1978_CR19","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/ana.410330605","volume":"33","author":"CJ Vecht","year":"1993","unstructured":"Vecht CJ, Haaxma-Reiche H, Noordijk EM et al (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33(6):583\u2013590","journal-title":"Ann Neurol"},{"issue":"8","key":"1978_CR20","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","volume":"18","author":"PD Brown","year":"2017","unstructured":"Brown PD, Ballman KV, Cerhan JH et al (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1049\u20131060","journal-title":"Lancet Oncol"},{"issue":"22","key":"1978_CR21","doi-asserted-by":"publisher","first-page":"8650","DOI":"10.1002\/cam4.3474","volume":"9","author":"GM Fischer","year":"2020","unstructured":"Fischer GM, Carapeto FCL, Joon AY et al (2020) Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: a fresh look at an old biomarker. Cancer Med 9(22):8650\u20138661","journal-title":"Cancer Med"},{"issue":"4","key":"1978_CR22","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0360-3016(96)00619-0","volume":"37","author":"L Gaspar","year":"1997","unstructured":"Gaspar L, Scott C, Rotman M et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4):745\u2013751","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"43","key":"1978_CR23","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102(43):15545\u201315550","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1978_CR24","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Martinez E et al (2013) Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4:2612","journal-title":"Nat Commun"},{"issue":"8","key":"1978_CR25","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M et al (2017) IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127(8):2930\u20132940","journal-title":"J Clin Invest"},{"issue":"1","key":"1978_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L et al (2016) Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 17(1):218","journal-title":"Genome Biol"},{"issue":"18","key":"1978_CR27","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1002\/sim.5762","volume":"32","author":"D Kuk","year":"2013","unstructured":"Kuk D, Varadhan R (2013) Model selection in competing risks regression. Stat Med 32(18):3077\u20133088","journal-title":"Stat Med"},{"issue":"2","key":"1978_CR28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00401-020-02256-1","volume":"141","author":"K Fukumura","year":"2021","unstructured":"Fukumura K, Malgulwar PB, Fischer GM et al (2021) Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis. Acta Neuropathol 141(2):303\u2013321","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1978_CR29","doi-asserted-by":"publisher","first-page":"100900","DOI":"10.1016\/j.xcrm.2022.100900","volume":"4","author":"AF Alvarez-Prado","year":"2023","unstructured":"Alvarez-Prado AF, Maas RR, Soukup K et al (2023) Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors. Cell Rep Med 4(1):100900","journal-title":"Cell Rep Med"},{"issue":"11","key":"1978_CR30","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","volume":"5","author":"PK Brastianos","year":"2015","unstructured":"Brastianos PK, Carter SL, Santagata S et al (2015) Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 5(11):1164\u20131177","journal-title":"Cancer Discov"},{"issue":"7528","key":"1978_CR31","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568\u2013571","journal-title":"Nature"},{"issue":"16","key":"1978_CR32","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1002\/cncr.26724","volume":"118","author":"JA Jakob","year":"2012","unstructured":"Jakob JA, Bassett RL Jr, Ng CS et al (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118(16):4014\u20134023","journal-title":"Cancer"},{"issue":"1","key":"1978_CR33","doi-asserted-by":"publisher","first-page":"e1057388","DOI":"10.1080\/2162402X.2015.1057388","volume":"5","author":"AS Berghoff","year":"2016","unstructured":"Berghoff AS, Fuchs E, Ricken G et al (2016) Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology 5(1):e1057388","journal-title":"Oncoimmunology"},{"issue":"38","key":"1978_CR34","doi-asserted-by":"publisher","first-page":"40836","DOI":"10.18632\/oncotarget.5696","volume":"6","author":"PN Harter","year":"2015","unstructured":"Harter PN, Bernatz S, Scholz A et al (2015) Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1\/PD-L1 immune checkpoints in human brain metastases. Oncotarget 6(38):40836\u201340849","journal-title":"Oncotarget"},{"issue":"8","key":"1978_CR35","doi-asserted-by":"publisher","first-page":"e2329186","DOI":"10.1001\/jamanetworkopen.2023.29186","volume":"6","author":"HN Vasudevan","year":"2023","unstructured":"Vasudevan HN, Delley C, Chen WC et al (2023) Molecular features of resected melanoma brain metastases, clinical outcomes, and responses to immunotherapy. JAMA Netw Open 6(8):e2329186","journal-title":"JAMA Netw Open"},{"key":"1978_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040731","author":"R V\u00e1raljai","year":"2021","unstructured":"V\u00e1raljai R, Horn S, Sucker A et al (2021) Integrative genomic analyses of patient-matched intracranial and extracranial metastases reveal a novel brain-specific landscape of genetic variants in driver genes of malignant melanoma. Cancers. https:\/\/doi.org\/10.3390\/cancers13040731","journal-title":"Cancers"},{"issue":"15","key":"1978_CR37","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/cncr.28029","volume":"119","author":"R Hamilton","year":"2013","unstructured":"Hamilton R, Krauze M, Romkes M et al (2013) Pathologic and gene expression features of metastatic melanomas to the brain. Cancer 119(15):2737\u20132746","journal-title":"Cancer"},{"issue":"1","key":"1978_CR38","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41467-020-15538-9","volume":"11","author":"A Mitra","year":"2020","unstructured":"Mitra A, Andrews MC, Roh W et al (2020) Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nat Commun 11(1):1839","journal-title":"Nat Commun"},{"issue":"4","key":"1978_CR39","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.ijrobp.2017.06.2454","volume":"99","author":"PW Sperduto","year":"2017","unstructured":"Sperduto PW, Jiang W, Brown PD et al (2017) Estimating survival in melanoma patients with brain metastases: an update of the graded prognostic assessment for melanoma using molecular markers (melanoma-molGPA). Int J Radiat Oncol Biol Phys 99(4):812\u2013816","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"32","key":"1978_CR40","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1200\/JCO.20.01255","volume":"38","author":"PW Sperduto","year":"2020","unstructured":"Sperduto PW, Mesko S, Li J et al (2020) Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol 38(32):3773\u20133784","journal-title":"J Clin Oncol"},{"issue":"8","key":"1978_CR41","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","volume":"6","author":"PL Chen","year":"2016","unstructured":"Chen PL, Roh W, Reuben A et al (2016) Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 6(8):827\u2013837","journal-title":"Cancer Discov"},{"issue":"23","key":"1978_CR42","doi-asserted-by":"publisher","first-page":"7037","DOI":"10.1158\/0008-5472.CAN-14-1392","volume":"74","author":"YN Gopal","year":"2014","unstructured":"Gopal YN, Rizos H, Chen G et al (2014) Inhibition of mTORC1\/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1alpha and oxidative phosphorylation in melanoma. Cancer Res 74(23):7037\u20137047","journal-title":"Cancer Res"},{"issue":"21","key":"1978_CR43","doi-asserted-by":"publisher","first-page":"6429","DOI":"10.1158\/1078-0432.CCR-19-0836","volume":"25","author":"YN Vashisht Gopal","year":"2019","unstructured":"Vashisht Gopal YN, Gammon S, Prasad R et al (2019) A novel mitochondrial inhibitor blocks MAPK pathway and overcomes MAPK inhibitor resistance in melanoma. Clin Cancer Res 25(21):6429\u20136442","journal-title":"Clin Cancer Res"},{"key":"1978_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000289","author":"D Chen","year":"2020","unstructured":"Chen D, Barsoumian HB, Fischer G et al (2020) Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2019-000289","journal-title":"J Immunother Cancer"},{"key":"1978_CR45","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124989","author":"YG Najjar","year":"2019","unstructured":"Najjar YG, Menk AV, Sander C et al (2019) Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.124989","journal-title":"JCI Insight"},{"issue":"8","key":"1978_CR46","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1158\/2326-6066.CIR-21-0870","volume":"10","author":"C Alvarez-Breckenridge","year":"2022","unstructured":"Alvarez-Breckenridge C, Markson SC, Stocking JH et al (2022) Microenvironmental landscape of human melanoma brain metastases in response to immune checkpoint inhibition. Cancer Immunol Res 10(8):996\u20131012","journal-title":"Cancer Immunol Res"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-01978-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-025-01978-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-01978-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:10:48Z","timestamp":1744715448000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-025-01978-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1978"],"URL":"https:\/\/doi.org\/10.1186\/s40478-025-01978-1","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"24 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MBM samples collected from patients who underwent craniotomy from 1991 to 2015 at MD Anderson Cancer Center was obtained from Central Nervous System (CNS) tissue bank and Melanoma Informatics, Tissue Resource, and Procurement Core (MelCore) facility under a protocol (LAB10-0519, titled \u201cThe Molecular Biology of Melanoma Brain Metastases\u201d) approved by the Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MAD has been a consultant to Replimmune, Roche\/Genentech, Array, Pfizer, Novartis, BMS, GSK, Sanofi-Aventis, Vaccinex, Apexigen, Eisai, Iovance, Merck, and ABM Therapeutics, and he has been the PI of research grants to MD Anderson by Roche\/Genentech, GSK, Sanofi-Aventis, Merck, Myriad, Oncothyreon, Pfizer, ABM Therapeutics, and LEAD Pharma. MSP receives research funding paid to her institution Sarah Cannon Research Institute, Nashville, TN, United States by Abbvie, Actuate Therapeutics, Affini-T Therapeutics, Agenus, Arcus Biosciences, Astellas, BeiGene, BioNTech, Bristol-Myers Squibb, Codiak Biosciences, Compass Therapeutics, CytomX, Eisai, Elevation Oncology, Elicio, Exelixis, Fate Therapeutics, Fog Pharmaceuticals, Gilead, GlaxoSmithKline, HiberCell, Immune-Onc Therapeutics, Impact Therapeutics, Jazz Pharmaceuticals, Kura Oncology, Leap Therapeutics, Neogene, Novartis, OncXerna Therapeutics, Panbela Therapeutics, Revolution Medicines, Roche, SeaGen, SQZ Biotechnologies, Surface Oncology, Tachyon Therapeutics, Takeda, Translational Genomics, TransThera Sciences, ZielBio, 1200 Pharma. MSP also has a consulting and advisory role, where she receive payments paid to her institution, in Arcus Biosciences, AstraZeneca, CytomX, Daiichi Sankyo, Elevation Oncology, EMD Serono, Ipsen Biopharmaceuticals, Jazz Pharmaceuticals, Pfizer, SeaGen, Stemline Therapeutics, Takeda. Dr. Jason T Huse, an author in this manuscript, is also one of the Editors-in-chief in the Acta Neuropathological communications journal. No other authors disclosed any conflicts of interest to the study presented here.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}